July 17 (UPI)-- A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report. Only about a third (35%) of babies eligible for nirsevimab got the injection during the 2023-24 RSV season, researchers reported Thursday in the journal Pediatrics . That was the first season that the monoclonal antibody jab was available to babies following its approval by the U.S. Food and Drug Administration , researchers said. "Notably, patients who were